Henry C Marsh Jr
Overview
Explore the profile of Henry C Marsh Jr including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
132
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Vitale L, He L, Thomas L, Wasiuk A, ONeill T, Widger J, et al.
Cancer Immunol Immunother
. 2020 May;
69(10):2125-2137.
PMID: 32451681
CD27 is a costimulatory molecule that provides a complementary target to the PD-1/PD-L1 checkpoint axis on T cells. Combining a CD27 agonist antibody with PD-1/PD-L1 blockade has shown synergistic antitumor...
2.
Vitale L, Thomas L, He L, ONeill T, Widger J, Crocker A, et al.
Cancer Immunol Immunother
. 2018 Nov;
68(2):233-245.
PMID: 30382327
Limitations of immunotherapy include poorly functioning events early in the immune response cycle, such as efficient antigen presentation and T cell priming. CD40 signaling in dendritic cells leads to upregulation...
3.
Thomas L, Vitale L, ONeill T, Dolnick R, Wallace P, Minderman H, et al.
Mol Cancer Ther
. 2016 Sep;
15(12):2946-2954.
PMID: 27671527
T-cell immunoglobulin and mucin domain 1 (TIM-1) is a type I transmembrane protein that was originally described as kidney injury molecule 1 (KIM-1) due to its elevated expression in kidney...
4.
Thomas L, Hammond R, Forsberg E, Geoghegan-Barek K, Karalius B, Marsh Jr H, et al.
Hum Vaccin
. 2008 Aug;
5(2):79-84.
PMID: 18670196
Cholesteryl ester transfer protein (CETP) is a plasma glycoprotein that facilitates the transfer of neutral lipids and phospholipids between lipoproteins and contributes to the regulation of the plasma concentration of...
5.
Lazar H, Keilani T, Fitzgerald C, Shapira O, Hunter C, Shemin R, et al.
Circulation
. 2007 Sep;
116(11 Suppl):I83-8.
PMID: 17846331
Background: TP10, a potent inhibitor of complement activation during cardiopulmonary bypass (CPB) has been shown to significantly reduce the incidence of death and myocardial infarction (MI) in high-risk male patients...
6.
Mocco J, Mack W, Ducruet A, King R, Sughrue M, Coon A, et al.
J Neurosurg
. 2006 Oct;
105(4):595-601.
PMID: 17044564
Object: Postischemic cerebral inflammatory injury has been extensively investigated in an effort to develop effective neuroprotective agents. The complement cascade has emerged as an important contributor to postischemic neuronal injury....
7.
Lazar H, Bokesch P, van Lenta F, Fitzgerald C, Emmett C, Marsh Jr H, et al.
Circulation
. 2004 Sep;
110(11 Suppl 1):II274-9.
PMID: 15364875
Background: This study was undertaken to determine whether soluble human complement receptor type 1 (TP10), a potent inhibitor of complement activation, would reduce morbidity and mortality in high-risk patients undergoing...
8.
Thomas L, Panneerselvam K, Beattie D, Picard M, Xu B, Rittershaus C, et al.
Glycobiology
. 2004 Jun;
14(10):883-93.
PMID: 15190008
Recombinant soluble human complement receptor type 1 (sCR1) is a highly glycosylated glycoprotein intended for use as a drug to treat ischemia-reperfusion injury and other complement-mediated diseases and injuries. sCR1-sLe(x)...
9.
Bradbury B, Bartyzel P, Kaufman T, Nieto M, Sindelar R, Scesney S, et al.
J Med Chem
. 2003 Jun;
46(13):2697-705.
PMID: 12801233
This paper reports the synthesis and the bioassay of 4-methoxy- and 4-hydroxyspiro[benzofuran-2(3H)-cyclohexane] partial analogues (5) of the complement inhibitory sesquiterpene fungal metabolite 6,7-diformyl-3',4',4a',5',6',7',8',8a'-octahydro-4,6',7'-trihydroxy-2',5',5',8a'-tetramethylspiro[1'(2'H)-naphthalene-2(3H)-benzofuran] (1a, K-76) and its silver oxide oxidized...